"The outbreak of Covid-19 has left us with no choice but to fight. China does not produce, so then trade decreases," the minister explained during a visit to the Dexa research facility in Cikarang, West Java, on Friday, February 21, 2020.
The situation presents an opportunity for domestic pharmaceutical industry to strengthen their position," the minister added.
The Covid-19 outbreak that occurred in China, since the end of 2019 until February 21, has infected 76,718 people in 28 countries and killed 2,247, mostly in mainland China.
The outbreak compelled China to isolate several cities, triggering the cessation of factory operations, including pharmaceutical firms.
This condition affects Indonesia that imports most pharmaceutical raw materials from China.
However, the health minister stated that the supply of Indonesian pharmaceutical raw materials would still suffice, and the government has encouraged the development of domestic pharmaceutical raw material production to reduce dependence on other countries.
"The most important aspect, as I have seen earlier, from our exposure, is that our supplies are sufficient. The most important point to be noted here is that raw materials originating from Indonesia are constantly driven to increase," he stated. (Antara)